CONFERENCE FORMAT CHANGE
We’re Going Virtual!
Due to social distancing and large group gathering restrictions, ACI’s Controlled Substances – Regulation, Litigation, and Enforcement has changed format from a live, in-person event to an interactive, virtual conference.
The conference will follow a similar schedule and agenda as originally planned.
Register for our one-of-a-kind, interactive virtual conference where stakeholders can gather with peers, discuss challenges, and walk away with tailored strategies for overcoming these challenges.
As our nation continues with attempts to combat the opioid overdose crisis, the regulations and requirements for stakeholders along the entire supply chain continue to evolve at a rapid pace. Recently the DOJ exercised its authority to reduce opioid production and DEA modified its opioid distribution quota rules in an attempt to minimize diversion. Further, state, city, and county litigations continue to escalate, with no end in sight.
EXCLUSIVE KEYNOTES FROM DEA, DOJ and FDA on ENFORCEMENT INITIATIVES
U.S. Drug Enforcement Administration
Dominic Chiapperino, Ph.D.
Director, Controlled Substance Staff, Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Director, Consumer Protection Branch
U.S. Department of Justice
Claire M. Brennan
Section Chief – Liaison Diversion Control Division
Drug Enforcement Administration
Scott A. Brinks
Regulatory Drafting & Policy Support Section
Diversion Control Division
Drug Enforcement Administration
Pre-Conference Workshops on July 20th are Included with Your Registration:
Hear from the Experts
Our faculty consisting of current and former DEA officials, DOJ representatives, in-house industry counsel, and outside counsel, will provide an up-to-date analysis of the current regulations, best practices for staying compliant, avoiding DEA investigations, and knowing how to respond when DEA comes knocking at your door.
Industry thought leaders will help you
- ANALYZE the implications of the proposed MDL settlement and the probability of a global settlement
- ASSESS the therapeutic potential of cannabinoids
- EVALUATE incentives for new medicines to treat pain and addiction
- DEVELOP a comprehensive controlled substances compliance program
Don’t miss this opportunity to benchmark your controlled substances strategies with top industry representatives.Register now
Here’s what some of our attendees had to say
This conference was spot on with the issues we are facing everyday.
It was great to hear from current and former industry leaders and experts from DEA, US AG offices, FDA, etc. Hearing about the current events and upcoming trends/expectations was valuable.
As the Director of Compliance for IPC, I was extremely pleased with last year’s speakers and the insight they provided into the latest controlled substance regulations.
ACI’s Global Series of Life Sciences Conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy. Learn More